Commercializing Rare-Disease Therapies Is Getting Tougher

Until the Evidence is There: A Conversation with Michael Sherman, Point32Health

Dodging the Sword: The Cost-Saving Opportunity in Biologicals

A Solution to the Medicare Copay Problem

Insights from PCMA: top market access signals

Paying for Gene/Cell Therapies is Only Half the Problem

On rare drugs, is ICER at least partly right?

The Medicare copay problem ain’t going away. Here’s how we can do better by patients.

It’s Time to Put Innovative Contracts Under Warranty

Survey Results: What (if any) drug pricing reform is likely to come in the next few years?